Genmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma
Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels